Company news
Unicycive Therapeutics, Inc. news in 2023
Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis
December 17, 2023
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
November 28, 2023
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023
Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)
October 22, 2023
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
September 5, 2023
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
August 28, 2023
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
July 19, 2023
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
July 17, 2023
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
June 28, 2023
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9: 00 A.M. ET
June 15, 2023
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
April 23, 2023
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
March 5, 2023
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
February 26, 2023
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
February 1, 2023
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
January 22, 2023
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
January 4, 2023